Esperion Therapeutics Inc (ESPR.OQ) Key Developments | Reuters.com
Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

9.80USD
1:15pm EDT
Change (% chg)

$0.14 (+1.45%)
Prev Close
$9.66
Open
$9.80
Day's High
$10.46
Day's Low
$9.70
Volume
338,557
Avg. Vol
132,532
52-wk High
$100.79
52-wk Low
$9.70

Latest Key Developments (Source: Significant Developments)

Esperion Therapeutics provides regulatory update for Bempedoic Acid
Tuesday, 28 Jun 2016 04:05pm EDT 

Esperion Therapeutics Inc : Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016 . Esperion expects full-year 2016 net cash used in operating activities to be between $65 to $75 million . Expects full-year 2016 cash and cash equivalents and investment securities to be approximately $220 million at December 31, 2016 . Current cash resources are expected to be sufficient to fund operations into early 2019 .Esperion Therapeutics provides clinical development and regulatory update for bempedoic acid.  Full Article

Esperion Therapeutics announces initiation of phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy
Tuesday, 12 Jan 2016 04:05pm EST 

Esperion Therapeutics Inc:Announced initiation of its Phase 2 pharmacokinetics/pharmacodynamics (PK/PD) study (ETC-1002-035) of bempedoic acid in patients treated with atorvastatin 80 mg, the most commonly prescribed high-dose statin.Expects to announce top-line results from the study by mid-year.  Full Article

Esperion Therapeutics announces positive top-line phase 2 results for etc-1002 in patients with hypercholesterolemia and hypertension
Tuesday, 28 Jul 2015 07:30am EDT 

Esperion Therapeutics Inc:Announces positive top-line phase 2 results for etc-1002 in patients with hypercholesterolemia and hypertension.Says the ldl-cholesterol lowering effect of ETC-1002 was statistically significant.Etc-1002 produced neutral effect on blood pressure, appeared safe and well-tolerated, produced no muscle-related adverse events.Says ETC-1002 appeared to be safe and well-tolerated and produced no muscle-related adverse events.  Full Article

Esperion Therapeutics announces closing of follow-on public offering
Tuesday, 24 Mar 2015 04:05pm EDT 

Esperion Therapeutics:Closes its follow-on public offering of 2,012,500 shares of common stock, offered at a price to the public of $100.00 per share, which includes the exercise in full by the underwriters of their option to purchase 262,500 additional shares of common stock.Says this exercise brings the net proceeds in the offering to $189.9 mln, after deducting underwriting discounts and commissions and estimated expenses payable by Esperion.Intends to use net proceeds from the offering, as well as its other existing capital resources, to complete the clinical development of ETC-1002.Including development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population.Also uses for initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event.Also uses for working capital, and for general corporate and administrative expenses.Credit Suisse Securities (USA) LLC acted as lead book-running manager for offering.RBC Capital Markets, LLC and UBS Securities LLC acted as joint book-running managers.JMP Securities LLC acted as lead manager.Stifel, Nicolaus & Company, Incorporated and Needham & Company, LLC acted as co-managers.  Full Article

Esperion Therapeutics Inc prices public offering of common stock
Wednesday, 18 Mar 2015 08:15pm EDT 

Esperion Therapeutics Inc:Announced pricing of underwritten public offering of 1,750,000 shares of its common stock, offered at price to public of $100.00 per share.Gross proceeds from this offering to Esperion are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion.Granted underwriters 30-day option to purchase up to an additional 262,500 shares of its common stock.Offering is expected to close on or about March 24.Intends to use net proceeds from offering, as well as its other existing capital resources, to complete the clinical development of ETC-1002, working capital, and for general corporate and administrative expenses.Credit Suisse Securities (USA) LLC is acting as lead book-running manager for proposed offering, with RBC Capital Markets, LLC and UBS Securities LLC acting as joint book-running managers.JMP Securities LLC acting as lead manager, and Stifel, Nicolaus & Company, Incorporated and Needham & Company, LLC acting as co-managers.  Full Article

Esperion Therapeutics Inc announces proposed public offering of common stock
Tuesday, 17 Mar 2015 05:28pm EDT 

Esperion Therapeutics Inc:Intends to offer and sell, subject to market and other conditions, $150 million of common stock in an underwritten public offering.Esperion expects to grant the underwriters 30-day option to purchase up to $22.5 million of additional shares of common stock.Credit Suisse Securities (USA) LLC is acting as lead book-running manager for proposed offering, with RBC Capital Markets, LLC and UBS Securities LLC acting as joint book-running managers.Esperion intends to use the net proceeds from offering, as well as other existing capital resources.to complete the clinical development of ETC-1002, Including development of fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in statin intolerant patient population.Initiation of cardiovascular outcomes trial for high-risk patients who have had cardiovascular event, working capital, and general corporate and administrative expenses.  Full Article

Esperion Therapeutics announces positive top-line phase 2b results for ETC-1002 added to stable statin therapy in patients with hypercholesterolemia
Tuesday, 17 Mar 2015 07:30am EDT 

Esperion Therapeutics Inc:Announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) compared with placebo in patients with hypercholesterolemia on stable statin therapy.Top-line results showed the 12-week study met its primary endpoint of greater LDL-cholesterol lowering from baseline with ETC-1002 compared with placebo.ETC-1002-treated patients achieved 17 and 24 percent incremental reductions in LDL-cholesterol at doses of 120 mg and 180 mg, respectively, compared with patients on stable statin therapy alone.  Full Article

Esperion Therapeutics Inc announces closing of follow-on public offering and exercise in full of underwriters' option to purchase additional shares of common stock
Tuesday, 21 Oct 2014 04:05pm EDT 

Esperion Therapeutics Inc:Closes follow-on public offering of 4,887,500 shares of common stock, offered at a price to the public of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase 637,500 additional shares of common stock.This exercise brings the net proceeds in the offering to $91.6 mln, after deducting underwriting discounts and commissions and expenses payable by Esperion.Intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through completion of the anticipated Phase 3 development program.Also use for regulatory compliance and the remainder for working capital and general corporate and administrative expenses.J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering, with JMP Securities, Stifel, and Needham & Company acting as co-managers for the offering.  Full Article

Esperion Therapeutics Inc prices public offering of common stock
Wednesday, 15 Oct 2014 08:00pm EDT 

Esperion Therapeutics Inc:Announces the pricing of an underwritten public offering of 4,250,000 shares of its common stock, offered at a price to the public of $20.00 per share.Says the gross proceeds from this offering to Esperion are expected to be $85 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion.Esperion has granted the underwriters a 30-day option to purchase up to an additional 637,500 shares of its common stock.The offering is expected to close on or about Oct. 21, 2014, subject to customary closing conditions.Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through the anticipated Phase 3 development program.Says which include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance.Says the remainder will be used for working capital and general corporate and administrative expenses.Says J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the offering.JMP Securities, Stifel, and Needham & Company acting as co-managers.  Full Article

Esperion Therapeutics Inc proposes public offering of common stock
Tuesday, 14 Oct 2014 04:05pm EDT 

Esperion Therapeutics Inc:Intends to offer and sell $85 mln of common stock in an underwritten public offering. Esperion expects to grant the underwriters a 30-day option to purchase up to $12.8 mln of additional shares of common stock.J.P. Morgan and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering.Intends to use the net proceeds as well as other existing capital resources, to fund the continued development of ETC-1002, which will include several clinical studies; chemistry, manufacturing and controls scale up and supplies development;.Net proceeds also use for regulatory compliance and the remainder for working capital and general corporate and administrative expenses.  Full Article

BRIEF-Esperion Therapeutics provides regulatory update for Bempedoic Acid

* Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016